We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4967:TSEKobayashi Pharmaceutical Co., Ltd. Analysis

Data as of 2026-08-31 - not real-time

¥5,690.00

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

Kobayashi Pharmaceutical Co., Ltd. is priced at ¥5,690.00, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 3.1%. Momentum indicators put RSI at 57.5 (neutral) with MACD reading bullish. Watch ¥5,446.00 as support and ¥5,739.00 as the nearer resistance level.
Valuation screens as overvalued, on a P/E of 263.2 with no clean sector comparison available. Consensus targets land 3.4% below where the shares trade now. The 1.86% dividend yield looks stretched against payout coverage.
The composite risk read is 3/10, putting it in low territory. With 30-day volatility of 23.1%, a beta of -0.11 and a maximum drawdown of 13.6%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.

Top Market Events

MarketWatch3monKobayashi Pharmaceutical 1Q Net Y1.Kobayashi Pharmaceutical Co shares in Japan are trading broadly stable in the wake of the company’sInvesting5monKobayashi Pharmaceutical Co LtdThe chart above depicts the distribution of Revenue for companies operating...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Trading above the 200-day average of 5572.74
  • MACD momentum is positive
  • RSI at 57.5 is in neutral territory

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Dividend yield of 1.86% looks stretched against payout coverage
  • Trading above the 200-day average of 5572.74
  • MACD momentum is positive

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Dividend yield of 1.86% looks stretched against payout coverage
  • Negative free cash flow
  • P/E ratio of 263.2

Key Metrics & Analysis

Financial Health

Revenue Growth1.80%
Profit Margin0.97%
P/E Ratio263.2
ROE0.78%
ROA2.53%
Debt/Equity0.34
P/B Ratio2.0
Op. Cash Flow¥11.8B
Free Cash Flow¥-12648875008

Technical Analysis

TrendNeutral
RSI57.5
Support¥5,446.00
Resistance¥5,739.00
MA 20¥5,592.50
MA 50¥5,563.48
MA 200¥5,572.75
MACDBullish
VolumeDecreasing
Fear & Greed Index94.18

Valuation

Fair Value¥2,308.65
Target Price¥5,496.25
Upside/Downside-3.41%
GradeOvervalued
TypeBlend
Dividend Yield1.86%

Risk Assessment

Beta-0.11
Volatility23.07%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.